Pioglitazone Holsten
Oral antidiabetic medication for type 2 diabetes mellitus
Quick Facts About Pioglitazone Holsten
Key Takeaways About Pioglitazone Holsten
- Reduces insulin resistance: Pioglitazone activates PPAR-gamma receptors, improving how muscle, fat, and liver cells respond to insulin and lowering blood glucose
- Takes 3–6 months for full effect: HbA1c reductions of approximately 0.5% to 1.5% develop gradually; effectiveness should be re-evaluated after 3 to 6 months
- Strict contraindications: Do not take if you have heart failure, liver disease, diabetic ketoacidosis, active or previous bladder cancer, or unexplained blood in urine
- Serious warnings: Watch for rapid weight gain, swelling, breathlessness (heart failure), bloody urine (bladder cancer), and new or worsening blurred vision (macular oedema)
- Fracture risk: Increased rate of bone fractures has been observed, especially in women; discuss bone health with your doctor before starting treatment
What Is Pioglitazone Holsten and What Is It Used For?
Pioglitazone Holsten contains the active substance pioglitazone, a thiazolidinedione (glitazone) used to treat type 2 diabetes mellitus in adults. It reduces insulin resistance in adipose tissue, skeletal muscle, and the liver, enabling the body to use its own insulin more efficiently to control blood glucose levels.
Type 2 diabetes mellitus is a chronic metabolic disorder that typically develops in adulthood and is characterised by insulin resistance – the body's inability to respond adequately to the insulin that the pancreas produces. Over time, elevated blood glucose levels can damage blood vessels and nerves, leading to serious complications affecting the heart, kidneys, eyes, and peripheral nerves. Pioglitazone Holsten is one of several medication classes used to manage this condition when lifestyle measures and first-line drugs are insufficient.
Pioglitazone works by selectively activating a nuclear receptor called peroxisome proliferator-activated receptor gamma (PPAR-gamma), which is expressed primarily in adipose tissue and, to a lesser extent, in skeletal muscle and the liver. Activation of PPAR-gamma alters the transcription of genes involved in glucose and lipid metabolism, ultimately improving insulin sensitivity in peripheral tissues and reducing hepatic glucose production. Unlike sulfonylureas, pioglitazone does not directly stimulate insulin secretion, so it carries a lower intrinsic risk of hypoglycaemia when used as monotherapy.
Pioglitazone Holsten may be prescribed in several clinical scenarios. It can be used as monotherapy, particularly in patients who cannot tolerate metformin or for whom metformin is contraindicated (for example, due to moderate to severe renal impairment), when diet and exercise alone have failed to achieve adequate glycaemic control. More commonly, however, it is used as add-on therapy in combination with metformin, a sulfonylurea (such as glibenclamide, gliclazide, or glimepiride), or insulin. Randomised controlled trials have shown that pioglitazone lowers glycated haemoglobin (HbA1c), a measure of long-term glucose control, by approximately 0.5% to 1.5% depending on the baseline value, dose, and combination used.
Your doctor will typically evaluate whether pioglitazone is working for you 3 to 6 months after treatment is started or the dose is adjusted. This evaluation interval reflects the gradual onset of action: although modest glucose-lowering effects may appear within a few weeks, the maximum improvement in insulin sensitivity and HbA1c develops over months. If target glucose levels are not achieved after this period, or if side effects outweigh benefits, pioglitazone should be discontinued and an alternative treatment considered.
Unlike metformin (which primarily reduces hepatic glucose production), sulfonylureas (which stimulate pancreatic insulin release), DPP-4 inhibitors (which enhance incretin hormone activity), or SGLT2 inhibitors (which promote urinary glucose excretion), pioglitazone works by making the body's own cells more responsive to insulin. Because the mechanism differs from that of other antidiabetic agents, pioglitazone often provides additive glucose-lowering benefit when combined with other classes. It has also been shown to raise HDL cholesterol, lower triglycerides, and reduce markers of hepatic steatosis in some patients.
What Should You Know Before Taking Pioglitazone Holsten?
Do not take Pioglitazone Holsten if you have heart failure, liver disease, diabetic ketoacidosis, bladder cancer (current or previous), or unexplained blood in urine. Inform your doctor about all medical conditions and medications before starting treatment, and attend all scheduled monitoring visits.
Contraindications
There are several absolute contraindications – situations in which pioglitazone must not be used under any circumstances. Review the following list with your doctor before your first prescription and whenever your medical history changes:
- Known hypersensitivity to pioglitazone or to any of the excipients listed in the package leaflet, including lactose monohydrate, hydroxypropylcellulose, carmellose calcium, and magnesium stearate
- Heart failure (any NYHA class) or a history of heart failure – pioglitazone can cause fluid retention that precipitates or worsens congestive cardiac symptoms
- Hepatic impairment – pioglitazone is extensively metabolised in the liver, and impaired hepatic function can lead to accumulation and an increased risk of toxicity
- Diabetic ketoacidosis – a life-threatening acute complication of diabetes that must be treated with intravenous insulin and fluid resuscitation, not oral agents
- Active bladder cancer or a history of bladder cancer – epidemiological studies have identified a small but significant increase in bladder cancer risk with long-term, high-dose pioglitazone exposure
- Uninvestigated macroscopic haematuria – visible blood in the urine must be investigated by a urologist before pioglitazone is initiated, because it can be an early sign of urothelial malignancy
Warnings and Precautions
Several conditions and risk factors require careful evaluation and close monitoring when pioglitazone is prescribed. Discuss the following with your doctor before starting treatment and at every follow-up appointment:
Fluid retention and heart failure: Pioglitazone causes dose-dependent fluid retention (peripheral oedema) that can unmask or worsen heart failure, particularly in patients older than 75 years, those with pre-existing cardiovascular disease, and those receiving combination therapy with insulin. Weigh yourself regularly – an unexplained gain of more than 2 to 3 kilograms within a week, especially if accompanied by ankle swelling or shortness of breath, warrants urgent medical review. If heart failure develops during treatment, pioglitazone should be discontinued.
Bladder cancer: A small increased risk of bladder cancer has been observed in patients taking pioglitazone, most notably with cumulative doses exceeding 28,000 mg and with treatment duration beyond two years. Risk factors such as age, smoking history, occupational exposure to aromatic amines, previous pelvic radiotherapy, and exposure to cyclophosphamide should be considered in the benefit-risk assessment. Report any haematuria, dysuria, urinary urgency, or pelvic discomfort to your doctor promptly.
Bone fracture risk: Long-term pioglitazone use has been associated with an increased rate of fractures, with the strongest signal in postmenopausal women. Fractures most commonly involve the distal upper limbs (forearm, hand, wrist) and lower limbs (ankle, foot, lower leg) rather than the classic osteoporotic fracture sites of the hip and vertebrae. Your doctor may recommend optimised bone health measures, including adequate calcium and vitamin D intake, regular weight-bearing exercise, smoking cessation, and moderation of alcohol consumption.
Macular oedema: Post-marketing reports have described cases of new-onset or worsening macular oedema – swelling at the back of the eye causing blurred central vision – in patients treated with pioglitazone. If you notice any change in your vision, arrange a prompt ophthalmological examination. Routine ophthalmological screening for diabetic retinopathy continues to be important during treatment.
Polycystic ovary syndrome (PCOS): Women with PCOS who take pioglitazone may experience a return of ovulation, which increases the likelihood of pregnancy. If you are of childbearing age and do not wish to become pregnant, discuss reliable contraception with your doctor before starting pioglitazone, as the medication is not recommended during pregnancy.
Liver function monitoring: Before starting pioglitazone, your doctor will measure serum transaminases (ALT and AST) to establish a baseline. Elevations above three times the upper limit of normal generally preclude treatment. Pioglitazone should be stopped if transaminase levels rise significantly during therapy or if symptoms suggestive of hepatic injury develop – unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, dark urine, or jaundice.
Contact your doctor immediately if you experience any of the following symptoms during treatment with Pioglitazone Holsten: unexpected or progressive shortness of breath, inability to lie flat comfortably (orthopnoea), waking at night gasping for breath, rapid weight gain exceeding 2 to 3 kilograms within a week, or swelling in the ankles, feet, or lower legs. These may be early signs of congestive heart failure, which requires prompt medical evaluation. The risk is substantially higher when pioglitazone is combined with insulin.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning a pregnancy, consult your doctor before taking Pioglitazone Holsten. There are insufficient safety data from the use of pioglitazone in pregnant women, and animal studies have shown reproductive toxicity at high doses. Your doctor will advise you to stop pioglitazone and switch to a better-characterised alternative – usually insulin – which remains the preferred treatment for hyperglycaemia during pregnancy. It is not known whether pioglitazone passes into human breast milk in clinically significant amounts, so breastfeeding is not recommended during treatment.
Driving and operating machinery: Pioglitazone does not directly impair the ability to drive or use machines. However, caution is warranted if you experience visual disturbances, and you should be aware that the risk of hypoglycaemia is increased when pioglitazone is combined with insulin or sulfonylureas. Hypoglycaemia can impair concentration, judgement, and reaction time, affecting the safety of driving. Always carry a source of fast-acting carbohydrate when driving if you are at risk.
Lactose content: Pioglitazone Holsten tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
How Does Pioglitazone Holsten Interact with Other Drugs?
Pioglitazone interacts significantly with gemfibrozil (which increases pioglitazone exposure up to threefold) and rifampicin (which reduces its effectiveness by about half). When combined with insulin or sulfonylureas, the risk of hypoglycaemia increases. Always tell your doctor and pharmacist about every medication, supplement, and herbal product you take.
Drug interactions can either amplify or reduce the effect of pioglitazone, or increase the risk of specific adverse events. Although most patients can continue their usual medications alongside pioglitazone, a few combinations require dose adjustment or additional monitoring. Keep an up-to-date list of all prescription medications, over-the-counter remedies, vitamins, and herbal supplements, and share it with every healthcare professional you consult.
Major Interactions
| Interacting Drug | Effect | Clinical Significance | Action Required |
|---|---|---|---|
| Gemfibrozil | Inhibits CYP2C8 metabolism, increasing pioglitazone plasma levels up to threefold | High – markedly higher exposure and side-effect risk | Consider pioglitazone dose reduction; monitor glucose, weight, and signs of fluid retention |
| Rifampicin | Strong CYP2C8 inducer; reduces pioglitazone exposure by approximately 54% | High – substantial loss of glycaemic control | Increase glucose monitoring; dose adjustment may be required |
| Insulin | Additive risk of hypoglycaemia and significantly increased risk of fluid retention and heart failure | High – cardiovascular adverse events | Monitor closely for oedema and heart failure; insulin dose reduction often needed |
| Sulfonylureas (glibenclamide, gliclazide, glimepiride) | Additive glucose-lowering effect, raising the risk of hypoglycaemia | Moderate | Sulfonylurea dose reduction may be required; educate patient on hypoglycaemia symptoms |
| NSAIDs (ibuprofen, naproxen, diclofenac) | Both NSAIDs and pioglitazone can cause fluid retention, amplifying oedema risk | Moderate | Use the lowest effective NSAID dose for the shortest duration; monitor weight and blood pressure |
| Trimethoprim | Weak CYP2C8 inhibitor; can modestly increase pioglitazone exposure | Low to moderate | No routine dose change, but monitor for enhanced side effects during concurrent use |
Minor Interactions
Pioglitazone is predominantly metabolised by the hepatic cytochrome P450 enzyme CYP2C8, with minor contributions from CYP3A4. Strong CYP2C8 inhibitors such as gemfibrozil produce the largest interaction, while moderate inhibitors (montelukast, quercetin) or inducers (aminoglutethimide) generally cause only modest changes in exposure that rarely require dose adjustment. Importantly, pioglitazone itself is not a potent inhibitor or inducer of CYP enzymes and therefore does not meaningfully alter the metabolism of oral contraceptives, digoxin, warfarin, or statins in clinical studies.
Certain herbal products can also influence blood glucose control. Cinnamon, bitter melon, fenugreek, ginseng, and chromium supplements may lower blood glucose and could theoretically increase the risk of hypoglycaemia when added to pioglitazone-based regimens. Always tell your doctor about any complementary or alternative therapies you use. Alcohol does not directly interact with pioglitazone, but heavy or regular consumption can raise the risk of hepatic injury and of hypoglycaemia when pioglitazone is used with insulin or sulfonylureas.
What Is the Correct Dosage of Pioglitazone Holsten?
The usual starting dose is 15 mg or 30 mg of pioglitazone once daily. Because Pioglitazone Holsten is supplied only as a 15 mg tablet, doses above 15 mg require multiple tablets or a different strength product. The tablet is taken with a glass of water, with or without food, at the same time each day. Always follow your doctor's specific instructions.
Always take Pioglitazone Holsten exactly as your doctor or pharmacist has told you. Do not change your dose or stop treatment without consulting your doctor first, as abrupt discontinuation can lead to a rapid rise in blood glucose. If you feel that the effect of the medication is too strong or too weak, discuss it with your doctor rather than adjusting the dose yourself.
Adults
Standard Adult Dosing
Starting dose: 15 mg (one Pioglitazone Holsten tablet) or 30 mg (two tablets) once daily
Titration: The dose may be increased gradually after several weeks based on HbA1c response and tolerability
Maximum dose: 45 mg once daily
Administration: Swallow the tablet whole with a glass of water, with or without food, at approximately the same time each day
Review: The need for continued treatment should be re-evaluated 3 to 6 months after initiation and at least annually thereafter
When Pioglitazone Holsten is added to a regimen that already includes metformin, a sulfonylurea, or insulin, your doctor may need to adjust the dose of the other medication – particularly the insulin or sulfonylurea – to reduce the risk of hypoglycaemia. Blood glucose, HbA1c, body weight, and signs of fluid retention should be checked regularly, and liver function tests may be repeated at intervals during treatment.
Continue to follow any dietary and lifestyle recommendations for type 2 diabetes, including carbohydrate-aware meal planning, regular physical activity, smoking cessation, and moderation of alcohol intake. These measures complement the pharmacological effect of pioglitazone and help protect against long-term complications of diabetes.
Children
Pioglitazone Holsten is not recommended for children or adolescents under 18 years of age. The safety and efficacy of pioglitazone have not been established in paediatric populations, and the rare but serious long-term risks (bladder cancer, bone fractures) are particularly concerning in individuals who might require decades of antidiabetic therapy. Paediatric type 2 diabetes should be managed by a specialist team using alternative treatment options.
Elderly
No routine dose adjustment is required solely on the basis of age. However, patients older than 75 years are at increased risk of fluid retention, heart failure, and fractures, and their overall cardiovascular and bone health should be assessed carefully before treatment. The starting dose should be low (usually 15 mg once daily), and treatment should be titrated slowly with close monitoring for oedema, weight gain, and changes in cardiac symptoms. A comprehensive medication review is advisable in older patients to minimise the risk of hypoglycaemia from combination therapy.
Patients with Renal Impairment
No dose adjustment is required in patients with renal impairment, because pioglitazone is metabolised hepatically and less than 2% of an oral dose is excreted unchanged in the urine. However, pioglitazone should not be used in patients on haemodialysis owing to limited data in this population. As renal function can deteriorate over time in people with diabetes, kidney function should be monitored at least annually during treatment.
Missed Dose
If you forget to take a dose, simply take your next scheduled dose at the usual time. Do not take a double dose to make up for a missed tablet, as this may increase the risk of side effects without providing additional glucose-lowering benefit. If you frequently miss doses, consider using a weekly pill organiser or setting a daily alarm, and discuss adherence strategies with your pharmacist.
Overdose
If you or someone else accidentally takes more Pioglitazone Holsten than prescribed – or if a child swallows tablets – contact a doctor, poison control centre, or the nearest emergency department immediately. Blood glucose may fall below normal levels, especially if pioglitazone is taken together with insulin or a sulfonylurea. If hypoglycaemia occurs and the person is conscious and able to swallow safely, treat it promptly with a fast-acting carbohydrate such as sugar cubes, glucose tablets, honey, or sweetened fruit juice. It is advisable to carry a glucose source at all times while taking antidiabetic medications.
Pioglitazone Holsten must be taken daily to maintain stable blood glucose control. If you stop taking the medication without your doctor's advice, your glucose levels may rise rapidly and your long-term diabetes control may deteriorate. Always consult your doctor before stopping treatment, and ask for a structured plan if a switch to another medication is required.
What Are the Side Effects of Pioglitazone Holsten?
Common side effects include upper respiratory tract infections, weight gain, numbness or tingling, and visual disturbances. Serious adverse events to watch for are heart failure (breathlessness, rapid weight gain, swelling), bladder cancer signs (blood in urine, dysuria), bone fractures, and macular oedema (blurred vision). Seek urgent medical review for any of these.
Like all medicines, Pioglitazone Holsten can cause side effects, although not everybody experiences them. Some reactions are minor and resolve as the body adjusts to the medication, while others are serious and require immediate medical attention. The risk profile of pioglitazone has been characterised in large randomised trials such as the PROactive study as well as in post-marketing pharmacovigilance programmes.
Serious Side Effects Requiring Immediate Attention
Heart failure: Congestive heart failure has been reported commonly (up to 1 in 10 patients) when pioglitazone is used together with insulin, and less commonly with monotherapy or other combinations. Typical symptoms include unexplained breathlessness, especially on exertion or lying flat, rapid weight gain, fatigue, and peripheral oedema. Patients older than 65 years and those with pre-existing cardiovascular disease are at greatest risk. Seek urgent medical review if these symptoms develop; pioglitazone will usually need to be discontinued.
Bladder cancer: An increased risk of bladder cancer has been identified in epidemiological studies, particularly with long duration of use and high cumulative exposure. Warning symptoms include visible blood in the urine (haematuria), pain or burning on urination (dysuria), sudden urges to urinate, and frequent daytime or nocturnal urination. Contact your doctor without delay if you notice any of these symptoms, and do not attribute them to a simple urinary tract infection without medical assessment.
Macular oedema: Blurring of central vision due to swelling or fluid accumulation at the back of the eye has been reported with pioglitazone (frequency unknown). Macular oedema may occur at any time during treatment and can progress to permanent visual loss if not detected and managed promptly. Contact your doctor or optometrist quickly if you develop new or worsening blurred vision, distorted lines, or difficulty reading.
Allergic reactions: Rarely, pioglitazone can cause hypersensitivity reactions, including urticaria (hives), angioedema (swelling of the face, lips, tongue, or throat, which can impair breathing or swallowing), and, very rarely, anaphylaxis. Stop the medication and seek emergency care immediately if such symptoms develop.
Side Effect Frequency Overview
Very Common (more than 1 in 10 people)
Primarily observed when pioglitazone is combined with other antidiabetic medicines
- Hypoglycaemia (low blood sugar), particularly with insulin or sulfonylureas
Common (up to 1 in 10 people)
May affect up to 1 in 10 patients
- Upper respiratory tract infection
- Visual disturbances, including blurred vision
- Weight gain
- Numbness or tingling in the hands or feet (paraesthesia)
- Headache
- Dizziness
- Joint pain (arthralgia)
- Erectile dysfunction
- Back pain
- Shortness of breath
- Mild reduction in red blood cell count (anaemia)
- Flatulence
- Heart failure (when combined with insulin)
- Peripheral oedema (when combined with insulin)
- Bone fractures, especially in women
Uncommon (up to 1 in 100 people)
May affect up to 1 in 100 patients
- Sinusitis
- Insomnia
- Glucose in the urine (glycosuria)
- Protein in the urine (proteinuria)
- Increased appetite
- Elevated liver enzymes
- Vertigo
- Excessive sweating
- Fatigue
- Bladder cancer
Rare (up to 1 in 1,000 people)
May affect up to 1 in 1,000 patients
- Marked elevation of hepatic transaminases
- Hepatitis (inflammation of the liver)
Frequency Not Known
Cannot be estimated from available data
- Allergic reactions (urticaria, angioedema, anaphylaxis)
- Macular oedema (blurred vision)
- Bone fractures in men
- Acute liver failure (very rare post-marketing reports)
Reporting suspected adverse reactions after a medicine has been authorised is essential for monitoring its ongoing benefit-risk balance. Patients and healthcare professionals are encouraged to report any suspected side effects to their national medicines regulatory authority – for example, the MHRA Yellow Card Scheme in the United Kingdom, the FDA MedWatch programme in the United States, or the EMA EudraVigilance network in the European Economic Area. Reports contribute to earlier detection of emerging safety signals and inform updates to prescribing information.
How Should You Store Pioglitazone Holsten?
Store Pioglitazone Holsten out of the sight and reach of children. No special temperature conditions are required; the tablets can be kept at room temperature in their original packaging. Do not use the medicine after the expiry date printed on the blister strip or carton.
Correct storage helps ensure that your medication remains safe and effective throughout its labelled shelf life. Follow the guidance below when you bring a new pack home:
- Keep out of the sight and reach of children at all times to prevent accidental ingestion; child-resistant storage boxes or high cupboards are recommended
- Check the expiry date printed on the carton and on each blister strip after the abbreviation "EXP". The expiry date refers to the last day of the stated month – do not use the tablets after this date
- No special storage conditions are required for this medicinal product; store at normal room temperature and protect from excessive humidity
- Keep the tablets in the original blister pack until you are ready to take them, in order to protect them from moisture and to preserve the lot information on the foil
- Safe disposal: Do not dispose of unused medicines via wastewater or household waste. Return expired or surplus tablets to your pharmacy, which will dispose of them through an environmentally appropriate take-back scheme. This helps protect waterways and wildlife from pharmaceutical contamination
What Does Pioglitazone Holsten Contain?
Each Pioglitazone Holsten tablet contains 15 mg of pioglitazone (as hydrochloride). Inactive ingredients include lactose monohydrate, hydroxypropylcellulose, carmellose calcium, and magnesium stearate.
Active Ingredient
The active substance is pioglitazone, present as pioglitazone hydrochloride. Each Pioglitazone Holsten tablet contains a quantity of pioglitazone hydrochloride equivalent to 15 mg of pioglitazone base. The drug belongs to the thiazolidinedione chemical class and is a selective agonist of PPAR-gamma.
Inactive Ingredients (Excipients)
- Lactose monohydrate – a filler commonly used in solid oral dosage forms
- Hydroxypropylcellulose – a binder that holds tablet ingredients together
- Carmellose calcium – a disintegrant that helps the tablet break down in the gastrointestinal tract
- Magnesium stearate – a lubricant that prevents tablet ingredients from sticking to manufacturing equipment
Tablet Appearance and Pack Sizes
| Strength | Appearance | Shape | Marking |
|---|---|---|---|
| 15 mg | White to off-white tablet | Round, flat, bevelled edges | Identifying embossment on one side |
Pioglitazone Holsten tablets are supplied in aluminium blister packs. Typical pack sizes include 14, 28, 56, 84, or 98 tablets; calendar blisters printed with abbreviated weekday names (Mon, Tue, Wed, Thu, Fri, Sat, Sun) help you keep track of your daily doses. Not all pack sizes are marketed in every country, and availability may vary by local regulatory approvals and distribution arrangements. Always check the label on your dispensed pack to confirm the strength, expiry date, and batch information.
Frequently Asked Questions About Pioglitazone Holsten
Pioglitazone Holsten is used to treat type 2 diabetes mellitus in adults. It helps control blood glucose by reducing insulin resistance, so your body can use its own insulin more effectively. It can be used as monotherapy when metformin is not suitable, or in combination with metformin, a sulfonylurea (such as glibenclamide or gliclazide), or insulin when these treatments alone have not achieved adequate blood sugar control.
Pioglitazone Holsten may take 3 to 6 months to reach its full therapeutic effect. Although modest blood glucose improvement may be seen within a few weeks, the maximum glucose-lowering effect builds gradually as insulin sensitivity improves in adipose tissue, skeletal muscle, and the liver. Your doctor will evaluate treatment effectiveness after this period – typically with an HbA1c test – and adjust therapy if the target has not been reached.
The most serious side effects are heart failure (especially in combination with insulin – watch for unexpected breathlessness, rapid weight gain, and swelling in the ankles or feet), bladder cancer (signs include blood in urine, painful urination, or urinary urgency), bone fractures (most commonly in postmenopausal women), and macular oedema (blurred vision due to swelling at the back of the eye). Contact your doctor promptly if any of these symptoms develop.
Yes, weight gain is a common side effect of pioglitazone and typically averages 2 to 3 kilograms over the first year of treatment. It arises through two mechanisms: fluid retention (which can also be an early warning sign of heart failure) and a redistribution of body fat into subcutaneous depots. Your doctor will monitor your weight at each visit, and you should report any rapid or unexplained gain – particularly if accompanied by ankle swelling or breathlessness – without delay.
Pioglitazone Holsten should not be taken by people with heart failure (current or past), hepatic impairment, diabetic ketoacidosis, active or previous bladder cancer, or uninvestigated blood in the urine. It is not recommended for children or adolescents under 18 years. Pregnant and breastfeeding women should not use this medication, and people who are hypersensitive to pioglitazone or any excipient – including those with rare lactose-related intolerances – should avoid it.
Yes. Clinically important interactions include gemfibrozil, which can triple pioglitazone blood levels, and rifampicin, which can reduce its effectiveness by approximately 54%. Combining pioglitazone with insulin or sulfonylureas increases the risk of hypoglycaemia, and insulin combinations also carry a higher risk of fluid retention and heart failure. NSAIDs can compound the oedema risk. Always give your doctor and pharmacist a complete list of your prescription, over-the-counter, and herbal medicines.
Pioglitazone Holsten is a generic version of pioglitazone, the same active substance found in the originator brand Actos. All generic pioglitazone products, including Pioglitazone Holsten, must meet strict regulatory bioequivalence standards, which means they deliver comparable amounts of pioglitazone into the bloodstream. Efficacy and the overall side-effect profile are equivalent to the brand product, although inactive ingredients and tablet appearance may differ.
References and Sources
- European Medicines Agency (EMA). Pioglitazone – Summary of Product Characteristics. Last updated 2024. Available at: www.ema.europa.eu
- Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. The Lancet. 2005;366(9493):1279–1289.
- American Diabetes Association. Standards of Medical Care in Diabetes – 2025. Diabetes Care. 2025;48(Supplement 1).
- National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management (NG28). Updated 2024. Available at: www.nice.org.uk/guidance/ng28
- World Health Organization (WHO). Model List of Essential Medicines. 23rd List, 2023. Available at: www.who.int
- U.S. Food and Drug Administration (FDA). Pioglitazone Prescribing Information (Actos and generic equivalents). Available at: www.fda.gov
- Liao HW, Saver JL, Wu YL, Chen TH, Lee M, Ovbiagele B. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open. 2017;7(1):e013927.
- British National Formulary (BNF). Pioglitazone. Available at: bnf.nice.org.uk
- Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314(3):265–277.
- Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31(5):845–851.
About the Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in endocrinology, clinical pharmacology, and internal medicine. All medical content adheres to international guidelines from the World Health Organization (WHO), the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), the National Institute for Health and Care Excellence (NICE), and the American Diabetes Association (ADA). Our editorial workflow includes multi-step fact-checking and peer review according to the GRADE evidence framework.
Evidence Level
Level 1A – Based on systematic reviews and meta-analyses of randomised controlled trials
Editorial Standards
No commercial funding. Independent editorial content produced under the GRADE methodology